questionsmedicales.fr
Composés chimiques organiques
Hydrocarbures
Hydrocarbures cycliques
Hydrocarbures aromatiques
Dérivés du benzène
Phénols
Catéchols
Masoprocol
Masoprocol : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Masoprocol
Diagnostic médical
Essais cliniques
Évaluation des symptômes
Symptômes
2
Inflammation
Cancer de la peau
Effets secondaires
Irritation cutanée
Prévention
2
Prévention des maladies
Traitement
Prévention
Exposition au soleil
Traitements
2
Traitement topique
Lésions cutanées
Administration locale
Crème
Complications
2
Complications
Infections cutanées
Interactions médicamenteuses
Consultation médicale
Facteurs de risque
2
Facteurs de risque
Allergies cutanées
Immunodépression
Surveillance médicale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Masoprocol : Questions médicales les plus fréquentes",
"headline": "Masoprocol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Masoprocol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-01",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Masoprocol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Catéchols",
"url": "https://questionsmedicales.fr/mesh/D002396",
"about": {
"@type": "MedicalCondition",
"name": "Catéchols",
"code": {
"@type": "MedicalCode",
"code": "D002396",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.455.426.559.389.657.166"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Masoprocol",
"alternateName": "Masoprocol",
"code": {
"@type": "MedicalCode",
"code": "D009637",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mohammed Baqur S Al-Shuhaib",
"url": "https://questionsmedicales.fr/author/Mohammed%20Baqur%20S%20Al-Shuhaib",
"affiliation": {
"@type": "Organization",
"name": "Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Sarfaraz Alam",
"url": "https://questionsmedicales.fr/author/Sarfaraz%20Alam",
"affiliation": {
"@type": "Organization",
"name": "Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland."
}
},
{
"@type": "Person",
"name": "Salman Ali Khan",
"url": "https://questionsmedicales.fr/author/Salman%20Ali%20Khan",
"affiliation": {
"@type": "Organization",
"name": "Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan."
}
},
{
"@type": "Person",
"name": "Hayder O Hashim",
"url": "https://questionsmedicales.fr/author/Hayder%20O%20Hashim",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Daniel H Obayes",
"url": "https://questionsmedicales.fr/author/Daniel%20H%20Obayes",
"affiliation": {
"@type": "Organization",
"name": "College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Involvement of CCCTC-binding factor in epigenetic regulation of cancer.",
"datePublished": "2023-10-15",
"url": "https://questionsmedicales.fr/article/37840067",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11033-023-08879-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characterization of a new CCCTC-binding factor binding site as a dual regulator of Epstein-Barr virus latent infection.",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36696451",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.ppat.1011078"
}
},
{
"@type": "ScholarlyArticle",
"name": "Long non-coding RNA HOTTIP induces inflammation in asthma by promoting EFNA3 transcription by CCCTC-binding factor.",
"datePublished": "2022-12-15",
"url": "https://questionsmedicales.fr/article/36628218",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "The HSV-1 encoded CCCTC-binding factor, CTRL2, impacts the nature of viral chromatin during HSV-1 lytic infection.",
"datePublished": "2024-10-07",
"url": "https://questionsmedicales.fr/article/39374265",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.ppat.1012621"
}
},
{
"@type": "ScholarlyArticle",
"name": "Active enhancers strengthen insulation by RNA-mediated CTCF binding at chromatin domain boundaries.",
"datePublished": "2023-01-17",
"url": "https://questionsmedicales.fr/article/36650052",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/gr.276643.122"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures",
"item": "https://questionsmedicales.fr/mesh/D006838"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrocarbures cycliques",
"item": "https://questionsmedicales.fr/mesh/D006844"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hydrocarbures aromatiques",
"item": "https://questionsmedicales.fr/mesh/D006841"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dérivés du benzène",
"item": "https://questionsmedicales.fr/mesh/D001555"
},
{
"@type": "ListItem",
"position": 7,
"name": "Phénols",
"item": "https://questionsmedicales.fr/mesh/D010636"
},
{
"@type": "ListItem",
"position": 8,
"name": "Catéchols",
"item": "https://questionsmedicales.fr/mesh/D002396"
},
{
"@type": "ListItem",
"position": 9,
"name": "Masoprocol",
"item": "https://questionsmedicales.fr/mesh/D009637"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Masoprocol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Masoprocol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Masoprocol",
"description": "Comment le masoprocol est-il diagnostiqué ?\nQuels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=CCCTC-Binding+Factor#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Masoprocol",
"description": "Quels symptômes le masoprocol peut-il traiter ?\nLe masoprocol provoque-t-il des effets secondaires ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=CCCTC-Binding+Factor#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Masoprocol",
"description": "Le masoprocol peut-il prévenir des maladies ?\nQuelles mesures préventives sont recommandées avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=CCCTC-Binding+Factor#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Masoprocol",
"description": "Dans quel type de traitement le masoprocol est-il utilisé ?\nComment le masoprocol est-il administré ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=CCCTC-Binding+Factor#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Masoprocol",
"description": "Quelles complications peuvent survenir avec le masoprocol ?\nLe masoprocol peut-il interagir avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=CCCTC-Binding+Factor#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Masoprocol",
"description": "Qui est à risque d'effets secondaires du masoprocol ?\nY a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=CCCTC-Binding+Factor#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le masoprocol est-il diagnostiqué ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes le masoprocol peut-il traiter ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés."
}
},
{
"@type": "Question",
"name": "Le masoprocol provoque-t-il des effets secondaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des irritations cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives sont recommandées avec le masoprocol ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition excessive au soleil et suivre les conseils médicaux."
}
},
{
"@type": "Question",
"name": "Dans quel type de traitement le masoprocol est-il utilisé ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés."
}
},
{
"@type": "Question",
"name": "Comment le masoprocol est-il administré ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement appliqué localement sous forme de crème ou de gel."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le masoprocol ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections cutanées peuvent survenir en cas d'irritation."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il interagir avec d'autres médicaments ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires du masoprocol ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2025
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :
A major global health burden continues to be borne by the complex and multifaceted disease of cancer. Epigenetic changes, which are essential for the emergence and spread of cancer, have drawn a huge ...
Distinct viral gene expression characterizes Epstein-Barr virus (EBV) infection in EBV-producing marmoset B-cell (B95-8) and EBV-associated gastric carcinoma (SNU719) cell lines. CCCTC-binding factor ...
Long non-coding RNAs (lncRNAs) function as vital regulators in biologic processes and are dysregulated in various tumors; however, little is known about their role in the inflammatory response in asth...
Asthma-related data resources from the Gene Expression Omnibus (GEO) database were extracted to explore the relationships between lncRNAs and asthma, and the lncRNA HOTTIP was identified. The probable...
HOTTIP was upregulated in asthmatic mice and downregulating HOTTIP in the mice model of asthma markedly reduced inflammation, and caused less infiltration of inflammatory cells, and secretions of IgE,...
HOTTIP facilitates the airway inflammatory response by regulating EFNA3 transcription, providing a therapeutic target for asthma....
HSV-1 genomes are rapidly heterochromatinized following entry by host cells to limit viral gene expression. Efficient HSV-1 genome replication requires mechanisms that de-repress chromatin associated ...
Vertebrate genomes are partitioned into chromatin domains or topologically associating domains (TADs), which are typically bound by head-to-head pairs of CTCF binding sites. Transcription at domain bo...
In humans and other eukaryotes, DNA is condensed into chromatin fibers that are further wound into chromosomes. This organization allows regulatory elements in the genome, often distant from each othe...
Epigenetic aberrations are suggested to play an important role in transcriptional alterations in Alzheimer's disease (AD). One of the key mechanisms of epigenetic regulation of gene expression is thro...
Sialylation on the crystallizable fragment (Fc) of anti-citrullinated protein antibodies (ACPAs), which is catalysed by β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1) could attenuate inflammation o...
Transcription factors interacting with the P2 promoter of ST6GAL1 were screened by DNA pull-down and LC-MS/MS, and verified by chromatin immunoprecipitation (ChIP), Dual luciferase reporter assay and ...
We observed that the level of ST6GAL1 and ACPAs sialylation decreased in serum of RA patients and were negatively correlated with DAS28 scores. Subsequently, CTCF was screened and verified as the tran...
CTCF is the specific transcription factor of ST6GAL1 in B cells which up-regulates the sialylation of ACPAs in RA and attenuates the disease progression....
Topologically Associating Domains (TADs) separate vertebrate genomes into insulated regulatory neighborhoods that focus genome-associated processes. TADs are formed by Cohesin-mediated loop extrusion,...
The ability of Epstein-Barr virus (EBV) to switch between latent and lytic infection is key to its long-term persistence, yet the molecular mechanisms behind this switch remain unclear. To investigate...